Patents by Inventor Geert Maertens
Geert Maertens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043938Abstract: The present invention generally relates to the field of cancer, in particular to cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency. Examples of such cancers include many colorectal, gastric, and endometrial tumors. Accordingly, the present invention provides a novel diagnostic marker panel for analyzing MSI loci, together with methods and kits of using said panel in the detection of cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency.Type: ApplicationFiled: June 9, 2023Publication date: February 8, 2024Inventors: Bram De Craene, Klaas Decanniere, Jan Van De Velde, Geert Maertens
-
Patent number: 11713488Abstract: The present invention generally relates to the field of cancer, in particular to cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency. Examples of such cancers include many colorectal, gastric, and endometrial tumors. Accordingly, the present invention provides a novel diagnostic marker panel for analyzing MSI loci, together with methods and kits of using said panel in the detection of cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency.Type: GrantFiled: January 22, 2019Date of Patent: August 1, 2023Assignee: BIOCARTIS NVInventors: Bram De Craene, Klaas Decanniere, Jan Van De Velde, Geert Maertens
-
Publication number: 20230220446Abstract: The field of the invention generally relates to cancer, including methods for diagnosing, prognosing, and treating cancer. In particular, the field of the invention relates to novel signatures of unique sets of point mutations involving a change of a cytosine or a guanidine, and methods, systems, and components thereof based upon the novel signature for identifying tumor samples having increased tumor mutational burden (TMB). Both the signatures and the methods, systems, and components thereof may be utilized for identifying cancer patients, microsatellite stable-cancer patients in particular, who will effectively respond to immune checkpoint blockade therapy.Type: ApplicationFiled: July 10, 2020Publication date: July 13, 2023Inventors: Jan VAN DE VELDE, Bram DE CRAENE, Aleksandra Katarzyna ZWOLINSKA, Hui ZHAO, Diether LAMBRECHTS, Geert MAERTENS
-
Patent number: 10196673Abstract: Improved compositions for and methods of processing and analyzing samples are described. In particular, the compositions and methods liberate nucleic acids from a biological sample allowing direct downstream processing of the nucleic acids in microfluidic systems. These compositions, methods and kits are useful in diagnosing, staging or otherwise characterizing various biological conditions.Type: GrantFiled: February 18, 2014Date of Patent: February 5, 2019Assignee: BIOCARTIS N.V.Inventors: Koen Van Acker, Bart Claes, Benoit Devogelaere, Geert Maertens, Erwin Sablon, Pascale Holemans, Tania Ivens
-
Publication number: 20160002706Abstract: Improved compositions for and methods of processing and analyzing samples are described. In particular, the compositions and methods liberate nucleic acids from a biological sample allowing direct downstream processing of the nucleic acids in microfluidic systems. These compositions, methods and kits are useful in diagnosing, staging or otherwise characterizing various biological conditions.Type: ApplicationFiled: February 18, 2014Publication date: January 7, 2016Inventors: Koen Van Acker, Bart Claes, BenoƮt Devogelaere, Geert Maertens, Erwin Sablon, Pascale Holemans, Tania Ivens
-
Patent number: 8859203Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: GrantFiled: June 27, 2003Date of Patent: October 14, 2014Assignee: Fujirebio Europe N.V.Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens
-
Patent number: 8835106Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: GrantFiled: May 22, 2007Date of Patent: September 16, 2014Assignee: Fujirebio Europe N.V.Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens
-
Publication number: 20120270208Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.Type: ApplicationFiled: May 23, 2012Publication date: October 25, 2012Applicant: INNOGENETICS, S.A.Inventors: Robert J. DELEYS, Dirk Pollet, Geert Maertens, Hugo Van Heuverswjn
-
Patent number: 8101351Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: July 12, 2007Date of Patent: January 24, 2012Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 7935490Abstract: The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent.Type: GrantFiled: August 2, 2006Date of Patent: May 3, 2011Assignee: N.V. InnogeneticsInventors: Geert Maertens, Joost Louwagie, Alfons Bosman, Erwin Sablon, Maan Zrein
-
Patent number: 7855052Abstract: The present application discloses and claims polynucleic acids relating to and/or containing HCV polynucleic acid sequences.Type: GrantFiled: November 30, 2006Date of Patent: December 21, 2010Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Publication number: 20100120121Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: ApplicationFiled: July 12, 2007Publication date: May 13, 2010Applicant: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Publication number: 20100099613Abstract: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.Type: ApplicationFiled: October 6, 2009Publication date: April 22, 2010Applicants: GENIMMUNE, PHARMEXA INC.Inventors: Marie-Ange Buyse, Geert Maertens, Erik Depla, Ignace Lasters, Johan Desmet, Denise Baker, Robert W. Chesnut, Mark Newman, Alessandra Sette, John Sidney, Scott Southwood
-
Publication number: 20090197244Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: ApplicationFiled: May 22, 2007Publication date: August 6, 2009Applicant: INNOGENETICS N.V.Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens
-
Publication number: 20080138894Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.Type: ApplicationFiled: February 23, 2007Publication date: June 12, 2008Applicant: INNOGENETICS N.V.Inventors: Geert Maertens, Fons Bosman, Guy De Martynoff, Marie-Ange Buyse
-
Patent number: 7313357Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: GrantFiled: June 4, 2003Date of Patent: December 25, 2007Assignee: Innogenetics N.V.Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens
-
Publication number: 20070243524Abstract: The present application discloses and claims polynucleic acids relating to and/or containing HCV polynucleic acid sequences.Type: ApplicationFiled: November 30, 2006Publication date: October 18, 2007Applicant: N.V. INNOGENETICS S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7258977Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position -291 to nucleotide at position -66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: April 14, 2003Date of Patent: August 21, 2007Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 7258982Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: April 13, 2004Date of Patent: August 21, 2007Assignee: Innogenetics, S.A.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 7255997Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as show in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: August 15, 2000Date of Patent: August 14, 2007Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver